Table 1.
Key features of wt and recombinant (R) viruses, of recombinant viral genomes (BAC), and of the parental viruses employed in this paper.
| Recombinant Virus * | Derived From | RETARGETING | ADDITIONAL MODIFICATIONS | Ref. | |||
|---|---|---|---|---|---|---|---|
| Insertion of scFv to ** | Insertion in | Genetic Modification *** | Site of Insertion | Purpose | |||
| R-593 | PSMA | gD Δ6–38 | This paper | ||||
| R-611 | EGFR | gD Δ6–38 | This paper | ||||
| R-613 | EGFRvIII | gD Δ6–38 | This paper | ||||
| R-615 | R-613 | EGFRvIII | gD Δ6–38 | mIL12 **** | US1-US2 | immunotherapy | This paper |
| R-613GLuc | R-613 | EGFRvIII | gD Δ6–38 | GLuc **** | UL37-UL38 | luciferase secretion | This paper |
| R-615GLuc | R-615 | EGFRvIII | gD Δ6–38 | mIL12 and GLuc | US1-US2 and UL37-UL38 | immunotherapy and luciferase secretion | This paper |
| R-LM113 | HER2 | gD Δ6–38 | [27] | ||||
| R-115 | R-LM113 | HER2 | gD Δ6–38 | mIL12 | US1-US2 | immunotherapy | This paper |
| R-LM249 | HER2 | gD Δ61–218 | [28] | ||||
| R-291 | R-LM249 | HER2 | gD Δ61–218 | D285N + A549T in gB | UL27 (gB) | enhanced infection or spread | This paper |
| Recombinant viral genome * | |||||||
| BAC-591 | PSMA | gD Δ61–218 | This paper | ||||
| BAC-621 | EGFR | gD Δ61–218 | This paper | ||||
| BAC-623 | EGFRvIII | gD Δ61–218 | This paper | ||||
| NO RETARGETING | |||||||
| Wt-virus and recombinant | Natural receptors | ||||||
| HSV-1(F) | Nectin1, HVEM | [49] | |||||
| R-LM5 | HSV-1(F) | Nectin1, HVEM | BAC sequences | UL3-UL4 | Genetic engineering in bacteria | [27] | |
All the recombinants derive from a backbone carrying pBeloBAC11 and EGFP inserted between UL3 and UL4 [27,50]. * Prefix R- denotes recombinant virus; prefix BAC denotes recombinant viral genome, as BAC-DNA. ** Size of inserts ranges between 747 and 801 bp, including flanking serine-glycine linkers upstream and/or downstream the scFv. *** Size of inserts: 1326 bp (GLuc cassette), 3200 bp (mIL12 cassette). **** mIL12 (murine interleukin 12); GLuc (Gaussia Luciferase).